Literature DB >> 30048919

MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder.

Ram Narayan1, Alexandra Simpson2, Katelyn Fritsche2, Sara Salama3, Santiago Pardo2, Maureen Mealy2, Friedemann Paul4, Michael Levy5.   

Abstract

MOG antibody disease is an autoimmune disease of the central nervous system associated with a serological antibody against MOG, myelin oligodendrocyte glycoprotein. MOG is a glycoprotein expressed on the outer membrane of myelin and solely found within the central nervous system, including in the brain, optic nerves and spinal cord. Clinically, the disease resembles neuromyelitis optica spectrum disorders in the predilection for relapses of optic neuritis and transverse myelitis. In addition, acute disseminated encephalomyelitis (ADEM) is a well-recognized phenotype of MOG antibody disease in children. In recent studies around the world where MOG testing is available, up to 42% of NMOSD patients who test seronegative for the AQP4 antibody test positive for MOG antibodies. MOG antibody disease has thus recently emerged as a distinct entity carved out of the patient population diagnosed with NMOSD. In this review, we examine the history of the MOG antibody and its relevance to demyelinating disease, as well as compare the clinical, radiographic and serological profiles of patients with MOG antibody with patients with AQP4 antibody.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30048919     DOI: 10.1016/j.msard.2018.07.025

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  44 in total

1.  Expanding the spectrum of MOG antibody disease.

Authors:  Michael Levy
Journal:  Mult Scler       Date:  2019-04-01       Impact factor: 6.312

Review 2.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

3.  Validation of claims-based diagnoses of adult and pediatric neuromyelitis optica spectrum disorder and variations in diagnostic evaluation and treatment initiation.

Authors:  Sabrina Gmuca; Duriel I Hardy; Sona Narula; Sharon Stoll; Julia Harris; Yongdong Zhao; Rui Xiao; Pamela F Weiss; Amy T Waldman; Jeffrey S Gerber
Journal:  Mult Scler Relat Disord       Date:  2019-11-01       Impact factor: 4.339

Review 4.  Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice.

Authors:  Amanda Marchionatti; Mark Woodhall; Patrick Joseph Waters; Douglas Kazutoshi Sato
Journal:  Neurol Sci       Date:  2020-10-15       Impact factor: 3.307

5.  Neuromyelitis optica spectrum disorder and adenocarcinoma of ovary: a novel association.

Authors:  Julie Sachdeva; Ramandeep Bansal; Aastha Takkar; Rajveer Singh
Journal:  BMJ Case Rep       Date:  2019-04-24

6.  Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis.

Authors:  E Bulut; J Karakaya; S Salama; M Levy; T A G M Huisman; I Izbudak
Journal:  AJNR Am J Neuroradiol       Date:  2019-03-07       Impact factor: 3.825

Review 7.  Magnetic resonance imaging in immune-mediated myelopathies.

Authors:  M J Wendebourg; S Nagy; T Derfuss; K Parmar; R Schlaeger
Journal:  J Neurol       Date:  2019-01-29       Impact factor: 4.849

8.  Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease.

Authors:  Sara Salama; Majid Khan; Michael Levy; Izlem Izbudak
Journal:  Mult Scler Relat Disord       Date:  2019-01-10       Impact factor: 4.339

9.  Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder.

Authors:  Sara Salama; Santiago Pardo; Michael Levy
Journal:  Mult Scler Relat Disord       Date:  2019-02-22       Impact factor: 4.339

10.  Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.

Authors:  Cristina Valencia-Sanchez; Dean M Wingerchuk
Journal:  BioDrugs       Date:  2020-12-10       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.